Comparison · NCT02694328-98e25fbb
Olanzapine vs ALKS 3831: Number of Participants Experiencing of Adverse Events (AEs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Olanzapine vs ALKS 3831: Number of Participants Experiencing of Adverse Events (AEs). Trial comparisons, record NCT02694328-98e25fbb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02694328-98e25fbb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.822 | 0.773 | 0.863 | wilson | |
| Risk in group 2 | 0.741 | 0.686 | 0.789 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0816 | 0.0125 | 0.15 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.11 | 1.02 | 1.21 | log | |
| Odds ratio, group 1 over group 2 | 1.62 | 1.07 | 2.44 | log | |
| Number needed to treat, for one more participant with the outcome on Olanzapine than on ALKS 3831 | 12.3 | 6.67 | 80.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Olanzapine | Administered as a coated bilayer tablet~Olanzapine: Daily dosing | 227 | 276 | OG000 |
| Group 2 | ALKS 3831 | Administered as a coated bilayer tablet~ALKS 3831: Daily dosing | 203 | 274 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Experiencing of Adverse Events (AEs)
- Description
- Time frame
- 24 weeks
- Population
- The Safety Population includes all randomized subjects who received at least 1 dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
- NCT number
- NCT02694328
- Phases
- PHASE3
- Conditions
- Schizophrenia
- Interventions
- ALKS 3831, Olanzapine
- Lead sponsor
- Alkermes, Inc.
- Results first posted
- 2020-02-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02694328?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02694328-98e25fbb